已收盤 02-06 16:00:00 美东时间
+0.400
+2.08%
今日重点评级关注:HC Wainwright & Co.:维持奥麦罗制药"买入"评级,目标价从20美元升至40美元;HC Wainwright & Co.:维持Cullinan Therapeutics"买入"评级,目标价从26美元升至27美元
01-09 20:22
今日重点评级关注:HC Wainwright & Co.:维持Assertio Holdings"买入"评级,目标价从3美元升至35美元;HC Wainwright & Co.:维持万达生物制药"买入"评级,目标价从20美元升至22美元
01-06 17:52
Morgan Stanley analyst Eric Serotta maintains Primo Brands (NYSE:PRMB) with a Overweight and lowers the price target from $28 to $26.
01-06 02:05
今日重点评级关注:Ascendiant Capital:维持Society Pass"买入"评级,目标价从22美元升至22.5美元;HC Wainwright & Co.:维持Climb Bio"买入"评级,目标价从9美元升至11美元
2025-12-19 10:15
JP Morgan analyst Andrea Teixeira maintains Primo Brands (NYSE:PRMB) with a Overweight and lowers the price target from $23 to $21.
2025-12-19 00:54
Resale of up to 116,210,806 Shares of Class A Common StockIssuance of up to 58,488 shares of Class A Common Stock underlying Options This prospectus relates to the (i) resale or other disposition of
2025-12-06 05:40
今日重点评级关注:HC Wainwright & Co.:维持BiomX"买入"评级,目标价从15美元升至26美元;Clear Street:维持Diversified Energy"买入"评级,目标价从23美元升至25美元
2025-11-26 10:07
Goldman Sachs analyst Bonnie Herzog maintains Primo Brands (NYSE:PRMB) with a Neutral and lowers the price target from $21 to $18.
2025-11-26 01:45
今日重点评级关注:Guggenheim:维持InflaRx"买入"评级,目标价从10美元升至22美元;巴克莱:维持Tandem糖尿病护理"超配"评级,目标价从51美元升至55美元
2025-11-11 10:49
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 17:17